Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Meta-Analysis as Topic | 18 | 2020 | 78 | 3.930 |
Why?
|
Research Design | 10 | 2024 | 573 | 2.830 |
Why?
|
Models, Statistical | 17 | 2024 | 307 | 2.710 |
Why?
|
Odds Ratio | 12 | 2024 | 769 | 1.770 |
Why?
|
Clinical Trials as Topic | 9 | 2020 | 453 | 1.690 |
Why?
|
Data Interpretation, Statistical | 11 | 2024 | 192 | 1.660 |
Why?
|
Computer Simulation | 15 | 2024 | 477 | 1.290 |
Why?
|
Chronic Pain | 2 | 2019 | 150 | 1.000 |
Why?
|
Probability | 7 | 2023 | 170 | 1.000 |
Why?
|
Randomized Controlled Trials as Topic | 8 | 2024 | 730 | 0.890 |
Why?
|
Algorithms | 5 | 2023 | 1003 | 0.880 |
Why?
|
Benzenesulfonates | 2 | 2013 | 13 | 0.810 |
Why?
|
Sirolimus | 2 | 2013 | 92 | 0.770 |
Why?
|
Pyridines | 2 | 2013 | 111 | 0.750 |
Why?
|
Carcinoma, Renal Cell | 2 | 2013 | 93 | 0.740 |
Why?
|
Multiple Sclerosis | 5 | 2023 | 217 | 0.710 |
Why?
|
Kidney Neoplasms | 2 | 2013 | 145 | 0.710 |
Why?
|
Likelihood Functions | 4 | 2019 | 69 | 0.710 |
Why?
|
Sample Size | 6 | 2023 | 65 | 0.690 |
Why?
|
Endpoint Determination | 2 | 2019 | 25 | 0.670 |
Why?
|
Colitis, Ulcerative | 1 | 2020 | 74 | 0.650 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 144 | 0.610 |
Why?
|
Health | 1 | 2018 | 31 | 0.590 |
Why?
|
Bias | 5 | 2023 | 112 | 0.590 |
Why?
|
Treatment Outcome | 9 | 2024 | 5596 | 0.580 |
Why?
|
Anesthesia | 5 | 2017 | 50 | 0.570 |
Why?
|
Humans | 69 | 2024 | 62865 | 0.560 |
Why?
|
Software | 2 | 2018 | 383 | 0.540 |
Why?
|
Propofol | 1 | 2017 | 24 | 0.540 |
Why?
|
Review Literature as Topic | 2 | 2015 | 37 | 0.500 |
Why?
|
Confidence Intervals | 2 | 2016 | 242 | 0.500 |
Why?
|
Health Status Indicators | 2 | 2015 | 93 | 0.480 |
Why?
|
Diagnostic Techniques and Procedures | 1 | 2015 | 9 | 0.480 |
Why?
|
Endometrial Ablation Techniques | 1 | 2013 | 6 | 0.420 |
Why?
|
Intrauterine Devices, Medicated | 1 | 2013 | 7 | 0.420 |
Why?
|
Menorrhagia | 1 | 2013 | 18 | 0.410 |
Why?
|
Menstruation | 1 | 2013 | 34 | 0.410 |
Why?
|
Biomedical Research | 1 | 2015 | 264 | 0.390 |
Why?
|
Economics, Pharmaceutical | 1 | 2011 | 1 | 0.370 |
Why?
|
Research Report | 1 | 2011 | 26 | 0.360 |
Why?
|
Pathology | 1 | 2010 | 12 | 0.340 |
Why?
|
Advisory Committees | 1 | 2011 | 112 | 0.340 |
Why?
|
Regression Analysis | 7 | 2019 | 497 | 0.320 |
Why?
|
Schools, Medical | 1 | 2010 | 145 | 0.320 |
Why?
|
Statistics as Topic | 4 | 2016 | 148 | 0.290 |
Why?
|
Antibodies, Viral | 2 | 2023 | 321 | 0.280 |
Why?
|
Practice Guidelines as Topic | 1 | 2011 | 727 | 0.260 |
Why?
|
Time Factors | 10 | 2020 | 3749 | 0.240 |
Why?
|
Female | 29 | 2023 | 32566 | 0.210 |
Why?
|
Cardiovascular Diseases | 3 | 2020 | 832 | 0.200 |
Why?
|
Male | 30 | 2023 | 29552 | 0.200 |
Why?
|
Patient Acceptance of Health Care | 1 | 2007 | 476 | 0.190 |
Why?
|
Pre-Eclampsia | 2 | 2020 | 73 | 0.190 |
Why?
|
Diagnosis | 2 | 2014 | 5 | 0.190 |
Why?
|
Burns | 4 | 1989 | 41 | 0.180 |
Why?
|
Suicide | 1 | 2023 | 126 | 0.180 |
Why?
|
Risk | 2 | 2019 | 377 | 0.180 |
Why?
|
Mesalamine | 1 | 2020 | 4 | 0.180 |
Why?
|
Neoplasms, Plasma Cell | 1 | 2020 | 3 | 0.170 |
Why?
|
Pain Measurement | 2 | 2019 | 343 | 0.170 |
Why?
|
Risk Assessment | 5 | 2019 | 2051 | 0.160 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 1 | 2020 | 33 | 0.160 |
Why?
|
Antidepressive Agents, Tricyclic | 1 | 2019 | 19 | 0.160 |
Why?
|
Disease Progression | 3 | 2020 | 1159 | 0.160 |
Why?
|
Linear Models | 6 | 2021 | 409 | 0.150 |
Why?
|
International Classification of Diseases | 3 | 2008 | 137 | 0.150 |
Why?
|
Physical Examination | 2 | 2018 | 112 | 0.150 |
Why?
|
Endoscopy | 2 | 2017 | 109 | 0.150 |
Why?
|
Biomarkers | 1 | 2023 | 1388 | 0.150 |
Why?
|
Survival Analysis | 1 | 2019 | 578 | 0.150 |
Why?
|
Health Care Surveys | 3 | 2005 | 285 | 0.140 |
Why?
|
Multivariate Analysis | 4 | 2014 | 934 | 0.140 |
Why?
|
Adolescent | 15 | 2008 | 6195 | 0.140 |
Why?
|
Demography | 3 | 2007 | 173 | 0.140 |
Why?
|
Interviews as Topic | 4 | 2008 | 506 | 0.140 |
Why?
|
Risk Adjustment | 2 | 2008 | 94 | 0.140 |
Why?
|
Sclerotherapy | 1 | 2017 | 9 | 0.140 |
Why?
|
Esophageal and Gastric Varices | 1 | 2017 | 11 | 0.140 |
Why?
|
Oximetry | 4 | 1993 | 48 | 0.130 |
Why?
|
Endoscopy, Gastrointestinal | 1 | 2017 | 74 | 0.130 |
Why?
|
Adult | 19 | 2014 | 16672 | 0.130 |
Why?
|
Effect Modifier, Epidemiologic | 1 | 2015 | 9 | 0.120 |
Why?
|
Numerical Analysis, Computer-Assisted | 1 | 2015 | 6 | 0.120 |
Why?
|
Liver Cirrhosis | 1 | 2017 | 171 | 0.120 |
Why?
|
Middle Aged | 16 | 2023 | 17391 | 0.120 |
Why?
|
Veterans | 1 | 2023 | 753 | 0.120 |
Why?
|
Hospital Mortality | 3 | 2008 | 867 | 0.110 |
Why?
|
Obesity | 2 | 2012 | 1230 | 0.110 |
Why?
|
Bayes Theorem | 2 | 2013 | 121 | 0.110 |
Why?
|
Hemagglutinins, Viral | 1 | 2014 | 12 | 0.110 |
Why?
|
History, 21st Century | 1 | 2015 | 170 | 0.110 |
Why?
|
Administration, Intravenous | 1 | 2014 | 66 | 0.110 |
Why?
|
Enterocolitis, Pseudomembranous | 1 | 2014 | 34 | 0.110 |
Why?
|
Mitochondria, Liver | 1 | 2014 | 13 | 0.110 |
Why?
|
History, 20th Century | 1 | 2015 | 230 | 0.110 |
Why?
|
Sirtuin 3 | 1 | 2014 | 12 | 0.110 |
Why?
|
Empirical Research | 1 | 2013 | 15 | 0.110 |
Why?
|
Diarrhea | 1 | 2014 | 76 | 0.110 |
Why?
|
Longevity | 1 | 2015 | 113 | 0.110 |
Why?
|
Anticoagulants | 1 | 2018 | 495 | 0.110 |
Why?
|
Drug Labeling | 1 | 2014 | 23 | 0.110 |
Why?
|
Computer Graphics | 1 | 1993 | 19 | 0.110 |
Why?
|
Oxidative Phosphorylation | 1 | 2014 | 41 | 0.110 |
Why?
|
Analgesics, Opioid | 1 | 2019 | 532 | 0.110 |
Why?
|
Danazol | 1 | 2013 | 1 | 0.110 |
Why?
|
Clinical Laboratory Techniques | 1 | 1993 | 45 | 0.110 |
Why?
|
Migraine Disorders | 1 | 2014 | 41 | 0.110 |
Why?
|
Levonorgestrel | 1 | 2013 | 10 | 0.110 |
Why?
|
Respiratory Tract Infections | 1 | 2014 | 89 | 0.100 |
Why?
|
Progestins | 1 | 2013 | 29 | 0.100 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 1993 | 44 | 0.100 |
Why?
|
Drainage, Postural | 1 | 1993 | 2 | 0.100 |
Why?
|
Health Surveys | 2 | 2006 | 313 | 0.100 |
Why?
|
United States | 10 | 2010 | 7744 | 0.100 |
Why?
|
Hospitalization | 1 | 2020 | 1346 | 0.100 |
Why?
|
Abdomen | 1 | 1993 | 92 | 0.100 |
Why?
|
Immunization Programs | 2 | 2003 | 14 | 0.100 |
Why?
|
Waist Circumference | 1 | 2012 | 45 | 0.100 |
Why?
|
Depression | 1 | 2019 | 884 | 0.090 |
Why?
|
Aged | 12 | 2015 | 14268 | 0.090 |
Why?
|
Influenza, Human | 1 | 2014 | 207 | 0.090 |
Why?
|
Quality Assurance, Health Care | 3 | 2006 | 252 | 0.090 |
Why?
|
Oxygen | 1 | 1993 | 316 | 0.090 |
Why?
|
Body Mass Index | 2 | 2012 | 864 | 0.090 |
Why?
|
Calcium Chloride | 2 | 1988 | 18 | 0.090 |
Why?
|
Women's Rights | 1 | 2010 | 6 | 0.090 |
Why?
|
Longitudinal Studies | 4 | 2008 | 1252 | 0.080 |
Why?
|
Physicians, Women | 1 | 2010 | 39 | 0.080 |
Why?
|
Diuretics | 2 | 2020 | 63 | 0.080 |
Why?
|
Analysis of Variance | 4 | 2020 | 608 | 0.080 |
Why?
|
Cimetidine | 1 | 1989 | 3 | 0.080 |
Why?
|
Color | 1 | 1988 | 25 | 0.070 |
Why?
|
Cosmetics | 1 | 1988 | 17 | 0.070 |
Why?
|
Predictive Value of Tests | 2 | 2008 | 1078 | 0.070 |
Why?
|
Multiple Sclerosis, Chronic Progressive | 1 | 2008 | 15 | 0.070 |
Why?
|
Anti-Bacterial Agents | 1 | 2014 | 786 | 0.070 |
Why?
|
Neuromuscular Junction | 1 | 1988 | 78 | 0.070 |
Why?
|
Multiple Sclerosis, Relapsing-Remitting | 1 | 2008 | 33 | 0.070 |
Why?
|
Nails | 1 | 1988 | 40 | 0.070 |
Why?
|
Adiposity | 1 | 2008 | 83 | 0.070 |
Why?
|
Neurology | 1 | 2008 | 40 | 0.070 |
Why?
|
Insurance Claim Review | 1 | 2007 | 76 | 0.070 |
Why?
|
Immunization | 2 | 2005 | 133 | 0.070 |
Why?
|
Gluconates | 1 | 1987 | 4 | 0.070 |
Why?
|
Quality Indicators, Health Care | 2 | 2008 | 334 | 0.070 |
Why?
|
Succinylcholine | 1 | 1987 | 10 | 0.070 |
Why?
|
Infant | 8 | 2005 | 1623 | 0.070 |
Why?
|
Calcium Gluconate | 1 | 1987 | 6 | 0.070 |
Why?
|
Child, Preschool | 9 | 2005 | 1962 | 0.070 |
Why?
|
Coronary Disease | 1 | 2008 | 246 | 0.070 |
Why?
|
Delivery of Health Care | 1 | 2011 | 432 | 0.070 |
Why?
|
Logistic Models | 5 | 2014 | 1275 | 0.070 |
Why?
|
Potassium | 1 | 1987 | 101 | 0.070 |
Why?
|
Sickness Impact Profile | 1 | 2007 | 46 | 0.070 |
Why?
|
Hospitals | 2 | 2007 | 393 | 0.070 |
Why?
|
Cardiovascular System | 1 | 1987 | 40 | 0.060 |
Why?
|
Neuromuscular Blocking Agents | 1 | 1986 | 13 | 0.060 |
Why?
|
Isoquinolines | 1 | 1986 | 33 | 0.060 |
Why?
|
Adrenergic beta-Antagonists | 1 | 1987 | 153 | 0.060 |
Why?
|
Emergency Service, Hospital | 1 | 2014 | 1079 | 0.060 |
Why?
|
Immunosuppressive Agents | 1 | 2008 | 377 | 0.060 |
Why?
|
Aged, 80 and over | 4 | 2015 | 5408 | 0.060 |
Why?
|
Income | 1 | 2007 | 169 | 0.060 |
Why?
|
Health Services Accessibility | 2 | 2008 | 554 | 0.060 |
Why?
|
Employment | 1 | 2007 | 127 | 0.060 |
Why?
|
Educational Status | 1 | 2007 | 273 | 0.060 |
Why?
|
Cohort Studies | 2 | 2014 | 2549 | 0.060 |
Why?
|
Costs and Cost Analysis | 1 | 2006 | 102 | 0.060 |
Why?
|
Random Allocation | 5 | 2005 | 198 | 0.060 |
Why?
|
Administration, Oral | 2 | 2018 | 367 | 0.060 |
Why?
|
Surgical Procedures, Operative | 1 | 2006 | 140 | 0.060 |
Why?
|
Stroke | 2 | 2018 | 1190 | 0.060 |
Why?
|
Health Status | 2 | 2006 | 433 | 0.060 |
Why?
|
Epstein-Barr Virus Nuclear Antigens | 1 | 2023 | 19 | 0.050 |
Why?
|
Attitude to Health | 1 | 2006 | 291 | 0.050 |
Why?
|
Fatigue Syndrome, Chronic | 1 | 2003 | 9 | 0.050 |
Why?
|
Databases, Factual | 1 | 2007 | 853 | 0.050 |
Why?
|
Pennsylvania | 3 | 2008 | 64 | 0.050 |
Why?
|
Antigens, Viral | 1 | 2023 | 134 | 0.050 |
Why?
|
Capsid Proteins | 1 | 2023 | 98 | 0.050 |
Why?
|
Natural Language Processing | 1 | 2023 | 47 | 0.050 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2023 | 102 | 0.050 |
Why?
|
Pregnancy | 2 | 2020 | 2326 | 0.050 |
Why?
|
Herpesvirus 4, Human | 1 | 2023 | 195 | 0.050 |
Why?
|
Reproducibility of Results | 2 | 2018 | 1640 | 0.050 |
Why?
|
Air Pollution | 1 | 2001 | 36 | 0.050 |
Why?
|
Massachusetts | 2 | 2006 | 2061 | 0.040 |
Why?
|
Social Determinants of Health | 1 | 2023 | 128 | 0.040 |
Why?
|
Prospective Studies | 5 | 2014 | 3263 | 0.040 |
Why?
|
Air Pollutants | 1 | 2001 | 93 | 0.040 |
Why?
|
Postoperative Complications | 1 | 2007 | 1284 | 0.040 |
Why?
|
Case-Control Studies | 1 | 2023 | 1115 | 0.040 |
Why?
|
Quality of Life | 1 | 2007 | 1221 | 0.040 |
Why?
|
Least-Squares Analysis | 2 | 1996 | 24 | 0.040 |
Why?
|
Risk Factors | 4 | 2014 | 5309 | 0.040 |
Why?
|
Information Systems | 1 | 2018 | 29 | 0.040 |
Why?
|
Hypocalcemia | 2 | 1989 | 19 | 0.040 |
Why?
|
Data Accuracy | 1 | 2018 | 32 | 0.040 |
Why?
|
Telephone | 3 | 2005 | 118 | 0.040 |
Why?
|
Publication Bias | 1 | 2018 | 20 | 0.040 |
Why?
|
Activities of Daily Living | 3 | 2008 | 294 | 0.040 |
Why?
|
Clinical Laboratory Information Systems | 2 | 2008 | 3 | 0.040 |
Why?
|
Insurance Claim Reporting | 2 | 2008 | 17 | 0.040 |
Why?
|
Dogs | 3 | 1989 | 325 | 0.040 |
Why?
|
Recurrence | 2 | 2008 | 636 | 0.030 |
Why?
|
Health Priorities | 1 | 1997 | 27 | 0.030 |
Why?
|
Venous Thromboembolism | 1 | 2018 | 148 | 0.030 |
Why?
|
Auranofin | 1 | 1996 | 3 | 0.030 |
Why?
|
Surveys and Questionnaires | 5 | 2007 | 2652 | 0.030 |
Why?
|
Patient Admission | 2 | 2007 | 190 | 0.030 |
Why?
|
Periodontal Diseases | 1 | 1995 | 17 | 0.030 |
Why?
|
Insurance, Health | 2 | 2008 | 151 | 0.030 |
Why?
|
Postoperative Period | 2 | 1993 | 138 | 0.030 |
Why?
|
Hemagglutination Inhibition Tests | 1 | 2014 | 8 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 2014 | 1140 | 0.030 |
Why?
|
Citrate (si)-Synthase | 1 | 2014 | 5 | 0.030 |
Why?
|
Socioeconomic Factors | 2 | 2008 | 775 | 0.030 |
Why?
|
Tryptamines | 1 | 2014 | 13 | 0.030 |
Why?
|
Placebos | 1 | 2014 | 71 | 0.030 |
Why?
|
Glucagon | 1 | 2014 | 33 | 0.030 |
Why?
|
Antibody Formation | 1 | 2014 | 113 | 0.030 |
Why?
|
Calcium | 2 | 1988 | 574 | 0.030 |
Why?
|
Datasets as Topic | 1 | 2013 | 26 | 0.030 |
Why?
|
Animals | 7 | 2014 | 20620 | 0.030 |
Why?
|
Gold | 1 | 1996 | 226 | 0.030 |
Why?
|
Triazoles | 1 | 2014 | 56 | 0.030 |
Why?
|
Lysine | 1 | 2014 | 82 | 0.030 |
Why?
|
Blood Pressure | 4 | 1991 | 514 | 0.030 |
Why?
|
Antirheumatic Agents | 1 | 1996 | 220 | 0.030 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2014 | 89 | 0.030 |
Why?
|
Sampling Studies | 2 | 2005 | 68 | 0.030 |
Why?
|
Food | 1 | 2014 | 76 | 0.030 |
Why?
|
Cyclic AMP | 1 | 2014 | 143 | 0.030 |
Why?
|
Age Factors | 4 | 2005 | 1556 | 0.030 |
Why?
|
Arginine | 1 | 2014 | 124 | 0.030 |
Why?
|
Family | 1 | 2015 | 240 | 0.030 |
Why?
|
Child | 5 | 1989 | 4477 | 0.020 |
Why?
|
Antibodies, Neutralizing | 1 | 2014 | 207 | 0.020 |
Why?
|
Alleles | 1 | 2014 | 449 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2014 | 305 | 0.020 |
Why?
|
Program Evaluation | 1 | 1994 | 486 | 0.020 |
Why?
|
Hepatocytes | 1 | 2014 | 216 | 0.020 |
Why?
|
Arthritis, Rheumatoid | 1 | 1996 | 331 | 0.020 |
Why?
|
Hemodynamics | 3 | 1991 | 242 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2014 | 283 | 0.020 |
Why?
|
Histamine Release | 1 | 1991 | 3 | 0.020 |
Why?
|
Metabolic Diseases | 1 | 2012 | 57 | 0.020 |
Why?
|
Leukotrienes | 1 | 1991 | 3 | 0.020 |
Why?
|
Prostaglandins | 1 | 1991 | 18 | 0.020 |
Why?
|
Lymph | 1 | 1991 | 10 | 0.020 |
Why?
|
Thromboxane B2 | 1 | 1991 | 17 | 0.020 |
Why?
|
Cardioplegic Solutions | 1 | 1991 | 9 | 0.020 |
Why?
|
Heart Arrest, Induced | 1 | 1991 | 13 | 0.020 |
Why?
|
Anaphylaxis | 1 | 1991 | 40 | 0.020 |
Why?
|
Peptic Ulcer Hemorrhage | 1 | 1991 | 3 | 0.020 |
Why?
|
Technology Assessment, Biomedical | 1 | 1991 | 12 | 0.020 |
Why?
|
Mass Screening | 1 | 1997 | 686 | 0.020 |
Why?
|
Incidence | 3 | 2003 | 1373 | 0.020 |
Why?
|
Energy Metabolism | 1 | 2014 | 378 | 0.020 |
Why?
|
Vaccination | 2 | 2005 | 356 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2014 | 1595 | 0.020 |
Why?
|
Mitochondria | 1 | 2014 | 370 | 0.020 |
Why?
|
Molecular Sequence Data | 1 | 2014 | 1997 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2014 | 875 | 0.020 |
Why?
|
Atrial Fibrillation | 1 | 2018 | 836 | 0.020 |
Why?
|
Hypercalcemia | 1 | 1989 | 8 | 0.020 |
Why?
|
Adenosine Triphosphate | 1 | 1991 | 292 | 0.020 |
Why?
|
Liver | 1 | 2014 | 846 | 0.020 |
Why?
|
Gastric Acid | 1 | 1989 | 10 | 0.020 |
Why?
|
Myocardium | 1 | 1991 | 275 | 0.020 |
Why?
|
Tubocurarine | 1 | 1988 | 2 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2014 | 2105 | 0.020 |
Why?
|
Nursing Homes | 1 | 1994 | 671 | 0.020 |
Why?
|
Spectrophotometry | 1 | 1988 | 35 | 0.020 |
Why?
|
Creatinine | 1 | 1989 | 135 | 0.020 |
Why?
|
Pulmonary Artery | 1 | 1989 | 93 | 0.020 |
Why?
|
Lung | 2 | 1991 | 939 | 0.020 |
Why?
|
Rural Health | 1 | 2008 | 15 | 0.020 |
Why?
|
Treatment Refusal | 1 | 2008 | 55 | 0.020 |
Why?
|
Drug Costs | 1 | 2008 | 56 | 0.020 |
Why?
|
Glucose | 1 | 1991 | 470 | 0.020 |
Why?
|
Plasma | 1 | 1988 | 37 | 0.020 |
Why?
|
Craniotomy | 1 | 2007 | 20 | 0.020 |
Why?
|
Mobility Limitation | 1 | 2008 | 49 | 0.020 |
Why?
|
Oxygen Consumption | 1 | 1988 | 209 | 0.020 |
Why?
|
Feedback | 1 | 1987 | 89 | 0.020 |
Why?
|
Sex Distribution | 1 | 2008 | 252 | 0.020 |
Why?
|
Mice | 2 | 2014 | 10819 | 0.020 |
Why?
|
Phenylephrine | 1 | 1987 | 18 | 0.020 |
Why?
|
Propanolamines | 1 | 1987 | 10 | 0.020 |
Why?
|
Health Services | 1 | 2008 | 82 | 0.020 |
Why?
|
Propranolol | 1 | 1987 | 20 | 0.020 |
Why?
|
Metoprolol | 1 | 1987 | 16 | 0.020 |
Why?
|
Hydrogen-Ion Concentration | 1 | 1989 | 455 | 0.020 |
Why?
|
Anesthesiology | 1 | 1987 | 41 | 0.020 |
Why?
|
Cost of Illness | 1 | 2008 | 161 | 0.020 |
Why?
|
Insulin | 1 | 1991 | 687 | 0.020 |
Why?
|
Models, Biological | 1 | 2012 | 1181 | 0.020 |
Why?
|
Cholesterol | 1 | 2008 | 259 | 0.020 |
Why?
|
Monitoring, Physiologic | 1 | 1988 | 151 | 0.020 |
Why?
|
Body Weight | 1 | 1988 | 377 | 0.020 |
Why?
|
Atracurium | 1 | 1986 | 2 | 0.020 |
Why?
|
Drug Evaluation | 1 | 1986 | 19 | 0.020 |
Why?
|
Histamine | 1 | 1986 | 21 | 0.020 |
Why?
|
Medical Records Systems, Computerized | 1 | 2007 | 61 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2014 | 3389 | 0.020 |
Why?
|
Double-Blind Method | 1 | 1988 | 739 | 0.020 |
Why?
|
Neoplasms | 1 | 1997 | 1350 | 0.020 |
Why?
|
Patient Compliance | 1 | 2008 | 358 | 0.020 |
Why?
|
Mycobacterium avium | 1 | 1985 | 5 | 0.020 |
Why?
|
BCG Vaccine | 2 | 1996 | 50 | 0.020 |
Why?
|
Coronary Artery Bypass | 1 | 2007 | 297 | 0.020 |
Why?
|
Mycobacterium Infections | 1 | 1985 | 16 | 0.020 |
Why?
|
Heart Rate | 1 | 1987 | 319 | 0.010 |
Why?
|
Thymectomy | 1 | 1985 | 34 | 0.010 |
Why?
|
Myasthenia Gravis | 1 | 1985 | 7 | 0.010 |
Why?
|
Child Day Care Centers | 1 | 2005 | 9 | 0.010 |
Why?
|
Maternal Age | 1 | 2005 | 34 | 0.010 |
Why?
|
Marital Status | 1 | 2005 | 45 | 0.010 |
Why?
|
Mycobacterium | 1 | 1985 | 36 | 0.010 |
Why?
|
Muscle Contraction | 1 | 1986 | 202 | 0.010 |
Why?
|
Plasma Exchange | 1 | 1985 | 24 | 0.010 |
Why?
|
Models, Theoretical | 1 | 2007 | 271 | 0.010 |
Why?
|
Psychometrics | 1 | 2007 | 377 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2006 | 729 | 0.010 |
Why?
|
Intubation, Intratracheal | 1 | 1986 | 203 | 0.010 |
Why?
|
Aortic Aneurysm, Abdominal | 1 | 2007 | 244 | 0.010 |
Why?
|
Forecasting | 1 | 2005 | 231 | 0.010 |
Why?
|
Kansas | 1 | 2003 | 3 | 0.010 |
Why?
|
Chronic Disease | 1 | 2007 | 749 | 0.010 |
Why?
|
Family Characteristics | 1 | 2003 | 44 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2008 | 536 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2008 | 1541 | 0.010 |
Why?
|
Aging | 1 | 1989 | 743 | 0.010 |
Why?
|
Hypertension | 1 | 2008 | 590 | 0.010 |
Why?
|
Breast Feeding | 1 | 2005 | 149 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2003 | 416 | 0.010 |
Why?
|
Urban Population | 1 | 2003 | 190 | 0.010 |
Why?
|
Tuberculosis | 2 | 1996 | 294 | 0.010 |
Why?
|
Sex Factors | 1 | 2005 | 975 | 0.010 |
Why?
|
United States Environmental Protection Agency | 1 | 2001 | 6 | 0.010 |
Why?
|
Vascular Resistance | 2 | 1991 | 48 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 1988 | 2179 | 0.010 |
Why?
|
Parents | 1 | 2005 | 381 | 0.010 |
Why?
|
Pulmonary Circulation | 2 | 1991 | 26 | 0.010 |
Why?
|
Mortality | 1 | 2001 | 160 | 0.010 |
Why?
|
Prevalence | 1 | 2003 | 1363 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2003 | 2444 | 0.010 |
Why?
|
Health Care Rationing | 1 | 1997 | 21 | 0.010 |
Why?
|
Binomial Distribution | 1 | 1996 | 4 | 0.010 |
Why?
|
Health Expenditures | 1 | 1997 | 122 | 0.010 |
Why?
|
Dental Scaling | 1 | 1995 | 1 | 0.010 |
Why?
|
Root Planing | 1 | 1995 | 2 | 0.010 |
Why?
|
Periodontal Index | 1 | 1995 | 4 | 0.010 |
Why?
|
Periodontal Attachment Loss | 1 | 1995 | 2 | 0.010 |
Why?
|
Muscle Rigidity | 1 | 1994 | 7 | 0.010 |
Why?
|
Pressure Ulcer | 1 | 1994 | 35 | 0.010 |
Why?
|
New York | 1 | 1994 | 144 | 0.010 |
Why?
|
Restraint, Physical | 1 | 1994 | 40 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2006 | 6545 | 0.010 |
Why?
|
Surgical Flaps | 1 | 1995 | 117 | 0.010 |
Why?
|
Meclofenamic Acid | 1 | 1991 | 1 | 0.010 |
Why?
|
Thromboxane-A Synthase | 1 | 1991 | 1 | 0.010 |
Why?
|
6-Ketoprostaglandin F1 alpha | 1 | 1991 | 1 | 0.010 |
Why?
|
Dinitrophenols | 1 | 1991 | 5 | 0.010 |
Why?
|
SRS-A | 1 | 1991 | 2 | 0.010 |
Why?
|
Leukotriene E4 | 1 | 1991 | 2 | 0.010 |
Why?
|
Chromones | 1 | 1991 | 20 | 0.010 |
Why?
|
Inpatients | 1 | 1994 | 302 | 0.010 |
Why?
|
Serum Albumin, Bovine | 1 | 1991 | 35 | 0.010 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 1991 | 45 | 0.010 |
Why?
|
Phosphocreatine | 1 | 1991 | 25 | 0.010 |
Why?
|
Imidazoles | 1 | 1991 | 80 | 0.010 |
Why?
|
Adenosine Diphosphate | 1 | 1991 | 41 | 0.010 |
Why?
|
Rats, Inbred Strains | 1 | 1991 | 150 | 0.010 |
Why?
|
Lactates | 1 | 1991 | 29 | 0.010 |
Why?
|
Glycogen | 1 | 1991 | 42 | 0.010 |
Why?
|
Comorbidity | 1 | 1994 | 1119 | 0.010 |
Why?
|
Sheep | 1 | 1991 | 179 | 0.010 |
Why?
|
Adenosine Monophosphate | 1 | 1991 | 28 | 0.010 |
Why?
|
Stroke Volume | 1 | 1991 | 328 | 0.010 |
Why?
|
Nifedipine | 1 | 1989 | 19 | 0.000 |
Why?
|
Vasoconstriction | 1 | 1989 | 22 | 0.000 |
Why?
|
Vasodilation | 1 | 1989 | 36 | 0.000 |
Why?
|
Research | 1 | 1990 | 192 | 0.000 |
Why?
|
In Vitro Techniques | 1 | 1989 | 487 | 0.000 |
Why?
|
Hypoxia | 1 | 1989 | 113 | 0.000 |
Why?
|
Citrates | 1 | 1988 | 17 | 0.000 |
Why?
|
Recovery Room | 1 | 1987 | 3 | 0.000 |
Why?
|
Infusions, Intravenous | 1 | 1988 | 174 | 0.000 |
Why?
|
Risk Management | 1 | 1987 | 39 | 0.000 |
Why?
|
Rats | 1 | 1991 | 1980 | 0.000 |
Why?
|
Documentation | 1 | 1987 | 127 | 0.000 |
Why?
|
Agglutination | 1 | 1985 | 5 | 0.000 |
Why?
|
Water Supply | 1 | 1985 | 13 | 0.000 |
Why?
|
Lymph Nodes | 1 | 1985 | 222 | 0.000 |
Why?
|
Preoperative Care | 1 | 1985 | 188 | 0.000 |
Why?
|
Infant, Newborn | 1 | 1988 | 1348 | 0.000 |
Why?
|
Respiration, Artificial | 1 | 1985 | 295 | 0.000 |
Why?
|
Intensive Care Units | 1 | 1985 | 405 | 0.000 |
Why?
|
Length of Stay | 1 | 1985 | 805 | 0.000 |
Why?
|
Cross-Sectional Studies | 1 | 1985 | 2558 | 0.000 |
Why?
|